Moderate

Chronic hepatitis C - direct-acting antiviral (DAA) therapy

Chronic HCV, DAA, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, pangenotypic, SVR · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic HCV (HCV RNA positive) is curable with 8-12 weeks of oral pangenotypic DAAs achieving sustained virological response (SVR, cure) in >95%. Treatment is recommended for ALL infected patients. Simplified genotype-free regimens apply to treatment-naive adults without cirrhosis or with compensated cirrhosis. Cure reduces progression, HCC risk and transmission.

Red flags

  • Decompensated cirrhosis (ascites, encephalopathy, variceal bleed) - changes regimen, specialist-led
  • HBV coinfection - reactivation during/after DAA (monitor ALT/HBV DNA)
  • Amiodarone + sofosbuvir - symptomatic bradycardia
  • Signs of hepatocellular carcinoma
  • Significant drug-drug interactions (anticonvulsants, rifampicin reduce DAA levels)

Assessment

Differential diagnosis

  • Other causes of raised ALT: MASLD, alcohol, HBV, autoimmune, haemochromatosis
  • HCV/HIV or HCV/HBV coinfection
  • Acute vs chronic HCV
  • Decompensated cirrhosis (changes regimen - no protease inhibitor)

Investigations

  • HCV antibody then confirmatory HCV RNA (viraemia); HCV genotype not needed for pangenotypic simplified therapy
  • Assess cirrhosis: FibroScan / FIB-4 / APRI; examine for decompensation
  • HBsAg, anti-HBc, HBV DNA (reactivation risk), HIV test, anti-HAV immunity
  • FBC, LFTs, U&E/eGFR, INR; baseline before and after therapy for SVR
  • Pregnancy test; full medication reconciliation for drug-drug interactions (statins, amiodarone, anticonvulsants, rifampicin, PPIs, ethinylestradiol)
  • HCV RNA at 12 weeks after end of treatment to confirm SVR12 (cure)

Management

  • Confirm viraemia (HCV RNA positive) and stage fibrosis (identify cirrhosis and whether compensated or decompensated)
  • Screen for HBV coinfection - risk of HBV reactivation during DAA therapy (prophylaxis/monitoring if HBsAg+)
  • Check comprehensive drug-drug interactions (use HEP drug interaction checker)
  • Select pangenotypic regimen: glecaprevir/pibrentasvir 8 weeks (no cirrhosis or compensated cirrhosis) OR sofosbuvir/velpatasvir 12 weeks
  • Decompensated (Child-Pugh B/C) cirrhosis: AVOID protease inhibitors (glecaprevir, voxilaprevir) - use sofosbuvir/velpatasvir +/- ribavirin, hepatology-led
  • Treat; counsel on adherence, reinfection risk, and avoiding alcohol
  • Confirm cure with HCV RNA (SVR12) 12 weeks after completion
  • After cure: continue HCC surveillance if cirrhosis (cure does NOT remove HCC risk in established cirrhosis); manage reinfection risk

Drugs & doses

Glecaprevir/pibrentasvir 300 mg/120 mg (3 tablets) PO once daily WITH food for 8 weeks (treatment-naive, no or compensated cirrhosis); 12-16 weeks in some experienced patients [verify local]
Sofosbuvir/velpatasvir 400 mg/100 mg (1 tablet) PO once daily for 12 weeks (pangenotypic alternative; usable across fibrosis stages)
Decompensated cirrhosis: sofosbuvir/velpatasvir + weight-based ribavirin 12 weeks (specialist) - NO protease inhibitor
Prior DAA failure / salvage: sofosbuvir/velpatasvir/voxilaprevir 12 weeks (not in decompensated cirrhosis)
Avoid glecaprevir/pibrentasvir in Child-Pugh B/C cirrhosis (hepatotoxicity)
Manage interactions: avoid/limit PPIs with some regimens, adjust statins, avoid amiodarone with sofosbuvir (bradycardia), ethinylestradiol contraindicated with glecaprevir/pibrentasvir
HBV prophylaxis (entecavir/tenofovir) if HBsAg+ during DAA therapy [verify local]

Disposition

Outpatient specialist/community HCV service. Hepatology for cirrhosis (especially decompensated), prior treatment failure, or complex interactions. Admit only for decompensation or HCC.

Complications & pitfalls

  • Cirrhosis, portal hypertension, decompensation
  • Hepatocellular carcinoma (risk persists after cure if cirrhotic)
  • HBV reactivation during therapy
  • Extrahepatic: cryoglobulinaemic vasculitis, membranoproliferative GN, lymphoma, porphyria cutanea tarda
  • Reinfection if ongoing exposure (not immunity-conferring)

Exam pearls

  • AASLD-IDSA HCV guidance: treat ALL patients with chronic HCV (except very short life expectancy) - pangenotypic DAAs cure >95% in 8-12 weeks.
  • Simplified genotype-FREE treatment applies to treatment-naive adults without cirrhosis or with compensated cirrhosis; genotype/RAS testing not required.
  • NEVER use a protease inhibitor (glecaprevir, voxilaprevir) in DECOMPENSATED (Child-Pugh B/C) cirrhosis - use sofosbuvir/velpatasvir-based therapy.
  • Always screen for HBV before DAAs - reactivation can be severe; monitor or give antiviral prophylaxis if HBsAg+.
  • Cure (SVR12) does NOT stop HCC surveillance in patients who already have cirrhosis. Check drug interactions every time (statins, amiodarone, anticonvulsants, PPIs).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.